Revenue Recognition (Tables)
|
9 Months Ended |
Sep. 30, 2024 |
|---|
| Revenue Recognition |
|
| Schedule of disaggregation of revenues by payer types |
| | | | | | | | | | | | | | | Three months ended | | Nine months ended | | | September 30, | | September 30, | | | 2024 | | 2023 | | 2024 | | 2023 | | | | (in thousands) | Insurance carriers | | $ | 405,208 | | $ | 239,780 | | $ | 1,130,364 | | $ | 676,680 | Laboratory and other partners | | | 27,622 | | | 21,731 | | | 70,152 | | | 71,985 | Patients | | | 6,928 | | | 6,795 | | | 20,334 | | | 22,801 | Total revenues | | $ | 439,758 | | $ | 268,306 | | $ | 1,220,850 | | $ | 771,466 |
|
| Schedule of total revenue by geographic area |
| | | | | | | | | | | | | | | | Three months ended | | Nine months ended | | | | September 30, | | September 30, | | | | 2024 | | 2023 | | 2024 | | 2023 | | | | | (in thousands) | | United States | | $ | 426,274 | | $ | 259,870 | | $ | 1,190,559 | | $ | 746,420 | | Americas, excluding U.S. | | | 2,002 | | | 1,288 | | | 5,084 | | | 3,652 | | Europe, Middle East, India, Africa | | | 7,722 | | | 5,255 | | | 18,339 | | | 16,071 | | Asia Pacific and Other | | | 3,760 | | | 1,893 | | | 6,868 | | | 5,323 | | Total revenues | | $ | 439,758 | | $ | 268,306 | | $ | 1,220,850 | | $ | 771,466 | |
|
| Schedule of beginning and ending balances of accounts receivable and deferred revenues |
| | | | | | | | | Balance at | | | September 30, | | December 31, | | | 2024 | | 2023 | | | | (in thousands) | Assets: | | | | | | | Accounts receivable, net | | $ | 306,876 | | $ | 278,289 | Liabilities: | | | | | | | Deferred revenue, current portion | | $ | 17,886 | | $ | 16,612 | Deferred revenue, long-term portion (1) | | | 16,916 | | | 19,128 | Total deferred revenues | | $ | 34,802 | | $ | 35,740 |
|
| Schedule of changes in the balance of deferred revenues |
| | | | | | | | | Balance at | | | September 30, | | | 2024 | | | 2023 | | | (in thousands) | Beginning balance | | $ | 35,740 | | $ | 30,778 | Increase in deferred revenues | | | 23,968 | | | 24,553 | Revenue recognized during the period that was included in deferred revenues at the beginning of the period | | | (12,102) | | | (9,610) | Revenue recognized from performance obligations satisfied within the same period | | | (12,804) | | | (9,676) | Ending balance | | $ | 34,802 | | $ | 36,045 |
|